Research programme: mental disorder therapeutics - Sunovion/PsychoGenics

Drug Profile

Research programme: mental disorder therapeutics - Sunovion/PsychoGenics

Alternative Names: SEP 360; SEP-378608

Latest Information Update: 24 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dainippon Sumitomo Pharma; Sunovion Pharmaceuticals
  • Developer PsychoGenics; Sunovion Pharmaceuticals
  • Class Antipsychotics; Neuropsychotherapeutics
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Mental disorders

Most Recent Events

  • 12 Jun 2017 Preclinical development is ongoing in USA
  • 12 Jun 2017 Sunovion files an IND application with the US FDA in USA for Mental disorders
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Mental-disorders in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top